Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 19, 2021.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Scott Perry, MD; Orrin Devinksy, MD; and Tracy Salazar, PhD, detail how seizure action plans change from pediatrics to adults and the need for adjustments in the fourth segment of this group discussion.
The study data revealed some of the more common and problematic symptoms, challenges, and comorbidities that persist for these individuals despite care.
The assistant professor of pediatric neurology at Washington University in St. Louis spoke to the results of a recent survey she and colleagues conducted around the diagnosis of cerebral palsy.
The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic discussed a recently initiated study that will look at the FDA-approved cancer drug lenalidomide for the treatment of Alzheimer disease.
The director of the Dartmouth Epilepsy Program provided an overview of some of the critical unmet needs within ongoing epilepsy research following the recent AES Annual Meeting.